FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017300925> ?p ?o ?g. }

• W3017300925 abstract "Background: Pancreatic cancer is one of the most aggressive malignancies. Bufalin, a traditional Chinese medicine, has been used to treat pancreatic cancer as an antitumor agent although the mechanism by which it exerts its effects is still unclear. c-Myc has been found to be overexpressed in more than half of human cancers including pancreatic cancer. However, the role of c-Myc in pancreatic cancer cells and its influence in bufalin-treated pancreatic cancer are yet to be clarified. The present study aimed to investigate the role of c-Myc in the antitumor activity of bufalin in pancreatic cancer. Methods: c-Myc siRNA and overexpression plasmid were transfected into pancreatic cancer cells to construct the cell models. c-Myc expression was detected via quantitative real-time polymerase chain reaction and western blot. The effect of c-Myc on bufalin-induced inhibition of cell proliferation was detected via CCK-8 assay. Cell apoptosis and the cell cycle were analyzed via flow cytometry. Cell invasion and migration was detected via Transwell and wound healing assays, respectively. In addition, the effect of bufalin on the suppression of tumor growth in vivo was studied in nude mice model subcutaneously injected with PANC-1 and SW1990 cells. Hematoxylin-eosin and terminal deoxynucleotidyl transferase dUTP nick-end labeling assay were used to evaluate pathological changes in vivo. The expression of HIF-1α/SDF-1/CXCR4 were detected via western blot. Results: CCK-8 assay showed that bufalin could inhibit the proliferation of pancreatic cancer cell, and c-Myc downregulation enhanced this effect. Similarly, c-Myc downregulation enhanced the effect of bufalin on cell cycle arrest, apoptosis, and the invasion and migration of pancreatic cancer cell in vitro. Further mechanism assay showed that c-Myc enhances the effect by regulating the HIF-1α/SDF-1/CXCR4 signaling pathway. The in vivo studies verified the results that c-Myc enhances the effect of bufalin through regulation of the HIF-1α/SDF-1/CXCR4 pathway. Conclusions: Downregulation of c-Myc enhanced the antitumor activity of bufalin in pancreatic cancer cells by suppressing the HIF-1α/SDF-1/CXCR4 pathway. These findings indicate that c-Myc inhibitors could enhance the clinical therapeutic effect of bufalin and may expand the clinical application of bufalin accordingly." @default.
• W3017300925 created "2020-04-24" @default.
• W3017300925 creator A5016415877 @default.
• W3017300925 creator A5034266315 @default.
• W3017300925 creator A5040162149 @default.
• W3017300925 creator A5049959303 @default.
• W3017300925 creator A5056817088 @default.
• W3017300925 creator A5073022594 @default.
• W3017300925 date "2020-04-17" @default.
• W3017300925 modified "2023-09-25" @default.
• W3017300925 title "Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells" @default.
• W3017300925 cites W1159008209 @default.
• W3017300925 cites W1757407923 @default.
• W3017300925 cites W1830728043 @default.
• W3017300925 cites W184250226 @default.
• W3017300925 cites W192226416 @default.
• W3017300925 cites W1959449289 @default.
• W3017300925 cites W1966802465 @default.
• W3017300925 cites W1990118372 @default.
• W3017300925 cites W1994269638 @default.
• W3017300925 cites W1995916680 @default.
• W3017300925 cites W2011810742 @default.
• W3017300925 cites W2019214567 @default.
• W3017300925 cites W2044012435 @default.
• W3017300925 cites W2049064891 @default.
• W3017300925 cites W2057612230 @default.
• W3017300925 cites W2075911047 @default.
• W3017300925 cites W2094421322 @default.
• W3017300925 cites W2156411980 @default.
• W3017300925 cites W2156883962 @default.
• W3017300925 cites W2157923000 @default.
• W3017300925 cites W2161577298 @default.
• W3017300925 cites W2162723598 @default.
• W3017300925 cites W2168050522 @default.
• W3017300925 cites W2170552969 @default.
• W3017300925 cites W2171407039 @default.
• W3017300925 cites W2221934150 @default.
• W3017300925 cites W2294409638 @default.
• W3017300925 cites W2404620725 @default.
• W3017300925 cites W2467520120 @default.
• W3017300925 cites W2618573553 @default.
• W3017300925 cites W2774807260 @default.
• W3017300925 cites W2791737096 @default.
• W3017300925 cites W2799630796 @default.
• W3017300925 cites W2915408681 @default.
• W3017300925 cites W2943554146 @default.
• W3017300925 cites W4211208840 @default.
• W3017300925 doi "https://doi.org/10.3389/fphar.2020.00495" @default.
• W3017300925 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7181899" @default.
• W3017300925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32362830" @default.
• W3017300925 hasPublicationYear "2020" @default.
• W3017300925 type Work @default.
• W3017300925 sameAs 3017300925 @default.
• W3017300925 citedByCount "16" @default.
• W3017300925 countsByYear W30173009252020 @default.
• W3017300925 countsByYear W30173009252021 @default.
• W3017300925 countsByYear W30173009252022 @default.
• W3017300925 countsByYear W30173009252023 @default.
• W3017300925 crossrefType "journal-article" @default.
• W3017300925 hasAuthorship W3017300925A5016415877 @default.
• W3017300925 hasAuthorship W3017300925A5034266315 @default.
• W3017300925 hasAuthorship W3017300925A5040162149 @default.
• W3017300925 hasAuthorship W3017300925A5049959303 @default.
• W3017300925 hasAuthorship W3017300925A5056817088 @default.
• W3017300925 hasAuthorship W3017300925A5073022594 @default.
• W3017300925 hasBestOaLocation W30173009251 @default.
• W3017300925 hasConcept C104317684 @default.
• W3017300925 hasConcept C119056186 @default.
• W3017300925 hasConcept C121608353 @default.
• W3017300925 hasConcept C126322002 @default.
• W3017300925 hasConcept C127561419 @default.
• W3017300925 hasConcept C1491633281 @default.
• W3017300925 hasConcept C150903083 @default.
• W3017300925 hasConcept C153911025 @default.
• W3017300925 hasConcept C185592680 @default.
• W3017300925 hasConcept C190283241 @default.
• W3017300925 hasConcept C207001950 @default.
• W3017300925 hasConcept C2777151579 @default.
• W3017300925 hasConcept C2780210213 @default.
• W3017300925 hasConcept C2780278673 @default.
• W3017300925 hasConcept C29537977 @default.
• W3017300925 hasConcept C502942594 @default.
• W3017300925 hasConcept C55493867 @default.
• W3017300925 hasConcept C62112901 @default.
• W3017300925 hasConcept C71924100 @default.
• W3017300925 hasConcept C86803240 @default.
• W3017300925 hasConcept C96232424 @default.
• W3017300925 hasConceptScore W3017300925C104317684 @default.
• W3017300925 hasConceptScore W3017300925C119056186 @default.
• W3017300925 hasConceptScore W3017300925C121608353 @default.
• W3017300925 hasConceptScore W3017300925C126322002 @default.
• W3017300925 hasConceptScore W3017300925C127561419 @default.
• W3017300925 hasConceptScore W3017300925C1491633281 @default.
• W3017300925 hasConceptScore W3017300925C150903083 @default.
• W3017300925 hasConceptScore W3017300925C153911025 @default.
• W3017300925 hasConceptScore W3017300925C185592680 @default.
• W3017300925 hasConceptScore W3017300925C190283241 @default.
• W3017300925 hasConceptScore W3017300925C207001950 @default.
• W3017300925 hasConceptScore W3017300925C2777151579 @default.
• W3017300925 hasConceptScore W3017300925C2780210213 @default.

• next